Sinclair Pharma announces possible merger with IS Pharma
Will create fully integrated pan-European specialist pharmaceutical company
Sinclair Pharma, headquartered in Godalming, Surrey, UK, and IS Pharma, based in Chester, Cheshire, are engaged in talks about a possible merger to create a fully integrated pan-European specialist pharmaceutical company called Sinclair IS Pharma.
It has been proposed that the merger would be by way of an all-share offer by Sinclair Pharma for the entire issued share capital of IS Pharma.
Sinclair Pharma shareholders would own 62.4% and IS Pharma shareholders 37.6% of Sinclair IS Pharma.
Sinclair Pharma said it would only make an offer if both companies complete their confirmatory due diligence and it has the unanimous and unqualified recommendation of IS Pharma’s board of directors.
If the merger goes ahead, the combined group would be headquartered in the UK with direct commercial operations in the UK, France, Germany, Italy, Spain and Ireland.
Sinclair IS Pharma will continue to focus on dermatology and specialist hospital therapies, including supportive oncology, critical care and wound care, as well as develop new opportunities.
